The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

For 2025, Barclays estimates market forecasts include expectations of 110 basis points in Medicare margin expansion, which is on the lower end of CVS’s target range of 100-200 bps.

Once Humira’s U.S. patents expired, CVS swooped in with Hyrimoz. In the three weeks after it hit the market, Chaguturu said that 93% of CVS prescriptions were filled with the new biosimilar.

On Feb. 5, drugstore chain CVS Caremark announced that it will stop selling tobacco products.It’s a big deal. Here’s why.It signals a step towards more businesses saying, “It’s wrong. So we’re ...

In the latest market close, CVS Health (CVS) reached $59.06, with a +1.2% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.41%. Elsewhere, the Dow lost 0.12% ...

CVS Health Corp. is tapping the investment-grade corporate bond market on Tuesday, with a five-part deal that’s expected to price later in the day.

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...